阿奇霉素序贯疗法联合孟鲁司特钠治疗小儿支原体肺炎的临床疗效及其安全性

Clinical efficacy and safety of azithromycin sequential therapy combined with montelukast sodium in the treatment of children with mycoplasma pneumonia

目的探讨阿奇霉素序贯疗法联合孟鲁司特钠治疗小儿支原体肺炎的临床疗效及其安全性。方法选取宁乡市人民医院2018年12月—2020年5月收治的支原体肺炎患儿72例,采用抽签法分为对照组和试验组,各36例。对照组采用阿奇霉素序贯法治疗,试验组采用阿奇霉素序贯疗法联合孟鲁司特钠治疗。比较2组临床疗效,治疗前后血清C反应蛋白(CRP)水平及免疫球蛋白水平(IgA、IgE、IgG),并比较2组啰音消失时间、咳嗽消失时间、退热时间、喘憋消失时间、住院时间、不良反应发生率。结果试验组总有效率高于对照组(P<0.05)。2组治疗前血清CRP水平比较,差异无统计学意义(P>0.05);治疗后试验组血清CRP水平低于对照组(P<0.05)。试验组IgA、IgE、IgG高于对照组,啰音消失时间、咳嗽消失时间、退热时间、喘憋消失时间、住院时间短于对照组(P<0.05)。试验组不良反应发生率低于对照组(P<0.05)。结论阿奇霉素序贯疗法联合孟鲁司特钠治疗小儿支原体肺炎的临床疗效确切,可以有效降低血清CRP水平,提高患儿免疫功能,缩短临床症状消失时间,且安全性较高。

Objective To investigate the clinical efficacy and safety of azithromycin sequential therapy combined with montelukast sodium in the treatment of children with mycoplasma pneumonia.Methods A total of 72 cases of children with mycoplasma pneumonia were selected from December 2018 to May 2020 in Ningxiang People’s Hospital,which were divided into control group and research group by drawing lots,36 cases in each group.The control group was treated with Azithromycin sequential therapy,and the experimental group was treated with Azithromycin sequential therapy combined with montelukast sodium.The clinical efficacy,serum C-reactive protein(CRP)levels and immunoglobulin levels(IgA,IgE,IgG)before and after treatment were compared between the two groups,and the disappearance time of rales,cough,fever,wheezing,hospitalization time and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the experimental group was higher than that of the control group(P<0.05).There was no significant difference in serum CRP level between the two groups before treatment(P>0.05);after treatment,the serum CRP level in the experimental group was lower than that in the control group(P<0.05).IgA,IgE and IgG in the experimental group were higher than those in the control group,and the disappearance time of rales,cough,fever,wheezing and hospitalization time in the experimental group were shorter than those in the control group(P<0.05).The incidence of adverse reactions in the experimental group was lower than that in the control group(P<0.05).Conclusion Azithromycin sequential therapy combined with montelukast sodium is effective in the treatment of mycoplasma pneumonia in children.It can effectively reduce the serum CRP level,improve the immune function of children,shorten the disappearance time of clinical symptoms,and with high safety.